Repligen Corporation (RGEN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RGEN Revenue Growth
Revenue Breakdown (FY 2025)
RGEN's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
RGEN Revenue Analysis (2014–2025)
As of May 8, 2026, Repligen Corporation (RGEN) generated trailing twelve-month (TTM) revenue of $763.3 million, reflecting strong growth of +14.8% year-over-year. The most recent quarter (Q1 2026) recorded $194.3 million in revenue, down 1.8% sequentially.
Looking at the longer-term picture, RGEN's 5-year compound annual growth rate (CAGR) stands at +15.0%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $801.5 million in 2022.
Revenue diversification analysis shows RGEN's business is primarily driven by Product (50%), Filtration Products (27%), and Chromatography Products (10%).
When compared to Healthcare sector peers including FTRE (+0.9% YoY), NTRA (+35.9% YoY), and AZTA (+1.8% YoY), RGEN has underperformed the peer group in terms of revenue growth. Compare RGEN vs FTRE →
RGEN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RGENCurrent | $763M | +14.8% | +15.0% | 8.1% | |
 FTRE | $2.7B | +0.9% | - | -1.1% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 AZTA | $594M | +1.8% | +8.9% | -1.9% | |
 BRKR | $3.4B | +0.4% | +11.6% | 6.9% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% |
RGEN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $738.3M | +16.4% | $347.6M | 47.1% | $59.6M | 8.1% |
| 2024 | $634.4M | +0.3% | $274.6M | 43.3% | $-35,114,000 | -5.5% |
| 2023 | $632.4M | -21.1% | $278.4M | 44.0% | $47.7M | 7.5% |
| 2022 | $801.5M | +19.5% | $455.7M | 56.9% | $224.7M | 28.0% |
| 2021 | $670.5M | +83.1% | $391.3M | 58.3% | $167.2M | 24.9% |
| 2020 | $366.3M | +35.5% | $194.4M | 53.1% | $81.3M | 22.2% |
| 2019 | $270.2M | +39.3% | $138.2M | 51.1% | $40.1M | 14.8% |
| 2018 | $194.0M | +37.4% | $108.1M | 55.7% | $26.0M | 13.4% |
| 2017 | $141.2M | +35.1% | $74.2M | 52.5% | $14.0M | 9.9% |
| 2016 | $104.5M | +25.1% | $57.4M | 54.9% | $16.0M | 15.3% |
See RGEN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RGEN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RGEN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRGEN — Frequently Asked Questions
Quick answers to the most common questions about buying RGEN stock.
Is RGEN's revenue growth accelerating or slowing?
RGEN maintains +14.8% revenue growth, in line with its 5-year CAGR of +15.0%. TTM revenue stands at $763M. Growth rate remains consistent with historical average.
What is RGEN's long-term revenue growth rate?
Repligen Corporation's 5-year revenue CAGR of +15.0% reflects the sustained expansion pattern. Current YoY growth of +14.8% is near this long-term average.
How is RGEN's revenue distributed by segment?
RGEN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.